Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00691691|
Recruitment Status : Unknown
Verified August 2011 by AHS Cancer Control Alberta.
Recruitment status was: Recruiting
First Posted : June 5, 2008
Last Update Posted : January 19, 2012
|Condition or disease||Intervention/treatment||Phase|
|Liver Tumors||Radiation: Stereotactic Body Radiation Therapy||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||71 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Fractionated Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors|
|Study Start Date :||November 2007|
Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
Radiation: Stereotactic Body Radiation Therapy
Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
- Response rate to SBRT [ Time Frame: 3-6 Months ]
- Treatment Related Toxicity [ Time Frame: 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00691691
|Contact: Robert Nordal, M.D.||403-521-3095||Robert.Nordal@albertahealthservices.ca|
|Tom Baker Cancer Centre||Recruiting|
|Calgary, Alberta, Canada, T2N 4N2|
|Contact: Robert Nordal, M.D. 403-521-3077 Robert.Nordal@albertahealthservices.ca|
|Principal Investigator: Robert Nordal, M.D.|
|Principal Investigator:||Robert Nordal, M.D.||Tom Baker Cancer Centre|